Literature DB >> 8023550

Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.

S Tamura1, A Yamanaka, M Shimohara, T Tomita, K Komase, Y Tsuda, Y Suzuki, T Nagamine, K Kawahara, H Danbara.   

Abstract

Cholera toxin B subunit (CTB) and Escherichia coli heat-labile toxin (LTB) (2 micrograms), each supplemented with a trace amount of cholera toxin (CT) (0.02-20 ng), were examined for the adjuvant effect on antibody (Ab) response against influenza inactivated HA (haemagglutinin) vaccine in Balb/c mice. Each mouse received a primary intranasal (i.n.) inoculation of the vaccine (1.5 micrograms) and the CT-containing CTB and in 4 weeks a second i.n. inoculation of the vaccine alone. The primary inoculation of the vaccine with CTB alone did not induce either anti-HA IgA or IgG Ab response, or haemagglutination-inhibition Ab responses in the serum. The vaccine with less than 2 ng of CT also failed to induce Ab response. On the other hand, the vaccine with CT-containing CTB induced a high Ab response, which increased depending on the CT dose. Moreover, the second vaccine induced a response more than ten times higher than the primary one and the response increased depending on the CT dose. Similar enhancement was found in the local anti-HA IgA Ab response in the nasal wash. Such synergistic effects were observed also between LTB and CT. The amount of Ab produced by the synergism was considered to be enough to protect against virus infection. These results suggest that CTB (or LTB) containing a trace amount of CT (about 0.1%) can be used practically as a potent adjuvant for nasal vaccination of humans against influenza.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8023550     DOI: 10.1016/0264-410x(94)90118-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  27 in total

1.  Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides.

Authors:  C D Partidos; P Vohra; M W Steward
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

2.  Induction of cell signaling events by the cholera toxin B subunit in antigen-presenting cells.

Authors:  Aletta C Schnitzler; Jennifer M Burke; Lee M Wetzler
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

3.  Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues.

Authors:  N Toida; G Hajishengallis; H Y Wu; M W Russell
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

4.  Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.

Authors:  Yongxin Zhang; Susan Pacheco; Catherine L Acuna; Kirsten C Switzer; Ying Wang; Xyanthine Gilmore; Gregory R Harriman; Innocent N Mbawuike
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin.

Authors:  G Douce; M Fontana; M Pizza; R Rappuoli; G Dougan
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

6.  Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.

Authors:  Dana Cechova; Michaela Novakova; Karel Mikulik; Olga Novotna; Jaroslav Julak; Peter Zanvit; Ludmila Prokesova
Journal:  Folia Microbiol (Praha)       Date:  2012-08-09       Impact factor: 2.099

7.  Intranasal antigen targeting to MHC class II molecules primes local IgA and serum IgG antibody responses in mice.

Authors:  D P Snider; B J Underdown; M R McDermott
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

8.  Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis.

Authors:  T G Blanchard; N Lycke; S J Czinn; J G Nedrud
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 9.  Mouse models for the study of mucosal vaccination against otitis media.

Authors:  Albert Sabirov; Dennis W Metzger
Journal:  Vaccine       Date:  2008-02-04       Impact factor: 3.641

10.  A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.

Authors:  M Roberts; A Bacon; R Rappuoli; M Pizza; I Cropley; G Douce; G Dougan; M Marinaro; J McGhee; S Chatfield
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.